Does GHK-Cu actually regrow hair? A closer look at the claims

What's this video probably claiming?

Based on the caption and the peptide category tag, @themultzz is almost certainly talking about GHK-Cu (copper peptide GHK-Cu) and its relationship to hair loss, specifically androgenic alopecia (AGA). The creator appears to be pushing back on a popular claim circulating in peptide communities: that GHK-Cu is a meaningful hair regrowth treatment. The caption's tone is skeptical and relatively measured, suggesting the creator acknowledges some possible adjunct benefit but is drawing a hard line between "might help a little" and "treats the underlying cause." This is a more responsible take than most TikTok peptide content, which tends to frame GHK-Cu as a near-miraculous follicle restorer. The peptide has genuine biological activity, and that's exactly why sorting signal from noise matters here.

What does the science actually show?

GHK-Cu does have real, peer-reviewed biological data behind it, which is more than can be said for many peptides trending on social media. Loren Pickart and colleagues have documented GHK-Cu's role in stimulating collagen synthesis, activating antioxidant pathways, and influencing gene expression related to wound healing and skin remodeling. A 2010 review by Pickart et al. in the Journal of Biomaterials Science confirmed its activity on skin repair. On hair specifically, a 2018 in vitro study by Park et al. in the Annals of Dermatology found GHK-Cu promoted hair follicle cell proliferation and upregulated Wnt/beta-catenin signaling at concentrations of 1-100 nanomolar. That sounds promising until you read the fine print: this was done on isolated dermal papilla cells, not on human scalps, and certainly not on scalps driven by DHT-mediated miniaturization, which is the actual mechanism of AGA.

Where does the social media noise diverge from clinical reality?

The gap is substantial. AGA is driven by dihydrotestosterone (DHT) binding to androgen receptors in genetically susceptible follicles, causing progressive miniaturization. Finasteride works by blocking 5-alpha reductase and reducing DHT by approximately 70% (Kaufman et al., 1998, Journal of the American Academy of Dermatology). Minoxidil prolongs the anagen growth phase through mechanisms that include KATP channel opening and possibly prostaglandin modulation. GHK-Cu does neither of these things. There is no human randomized controlled trial showing GHK-Cu significantly reverses or halts AGA progression. The in vitro and animal data are biologically interesting but not clinically actionable. Social media content routinely conflates "activates follicle cells in a dish" with "regrows hair on a DHT-damaged scalp," and those are not remotely the same claim. The creator seems to understand this distinction, which puts them ahead of most peptide influencers.

What should you actually know?

The creator's framing appears scientifically honest. At best, GHK-Cu might play a supportive role in scalp health through its anti-inflammatory and collagen-stimulating properties, and there's a theoretical argument that a healthier scalp environment could modestly support existing first-line treatments. But it does not address androgen signaling, it does not block DHT, and there is no clinical evidence it reverses miniaturization on its own. Anyone spending money on topical or systemic GHK-Cu as a primary hair loss strategy is likely wasting it if they have confirmed AGA. If you are losing hair and suspect AGA, the evidence-based options remain finasteride, dutasteride, and minoxidil, with or without low-level laser therapy as an adjunct. Peptides are not an equivalent substitute for those interventions.